Objective To evaluate the effect of vardenafil in the treatment of pneumoconiosis patients com-plicated with pulmonary arterial hypertension. Methods 33 pneumoconiosis patients complicated with pulmonary ar-terial hypertension were randomly divided into the treatment group ( n=22 ) and the control group ( n=11 ) . The treatment group was given vardenafil orally 5mg once everyday for 4 weeks, and it was sequentially increased to twice a day of 5mg if no adverse drug reactions occurred. The total course of treatment was 12 weeks. The control group was given the same dose of placebo. Before and after the treatment, 6-minute walking distance, pulmonary arterial pressure, Borg scale scores and SaO2 were measured. Results There was no significant difference in age and severi-ty of illness (6-min walk distance, pulmonary arterial pressure, Borg scale scores and SaO2)before the treatment. 12 weeks after the treatment, the parameters abov improved more obviously in the treatment group than in the control group (P<0. 05). There were mild adverse reactions in the treatmen group. Conclusion Vardenafil is not only an effective drug but also has good tolerance in the treatment of pneumoconiosis patients complicated with pulmonary ar-terial hypertension.%目的：探讨伐地那非治疗尘肺合并肺动脉高压患者的疗效。方法33例尘肺合并肺动脉高压患者随机分成治疗组(n=22)和对照组(n=11),治疗组给予伐地那非口服,每日1次,每次5mg,持续4周,若没有严重药物不良反应发生,增加到目标剂量每日2次,每次5mg,12周为一疗程；对照组口服相同剂量的安慰剂,对比两组患者治疗前后6分钟步行距离、肺动脉压、Borg呼吸困难评分、动脉血学氧饱和度。结果两组患者在年龄、病情严重程度(6分钟步行距离、肺动脉压、Borg呼吸困难评分、血氧饱和度)差异无统计学意义(P>0．05)；在12周后,治疗组6分钟步行距离、肺动脉压、Borg呼吸困难评分、血氧饱和度明显改善,差异具有统计学意义(P<0．05),但对照组上述指标无明显改变(P>0．05),治疗组只有轻微短暂的不良反应。结论在尘肺合并肺动脉高压患者中,伐地那非疗效明确且耐受性良好。
展开▼
